
Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Keratoconjunctivitis sicca (Dry Eye) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2022, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline landscape.
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 25, 37, 16, 2, 53, 10 and 7 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.
Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2022, provides an overview of the Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline landscape.
Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis Sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 25, 37, 16, 2, 53, 10 and 7 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 1 molecules, respectively.
Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis Sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
280 Pages
- Introduction
- Global Markets Direct Report Coverage
- Keratoconjunctivitis Sicca (Dry Eye) – Overview
- Keratoconjunctivitis Sicca (Dry Eye) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Keratoconjunctivitis Sicca (Dry Eye) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Keratoconjunctivitis Sicca (Dry Eye) – Companies Involved in Therapeutics Development
- AB2 Bio Ltd
- AbbVie Inc
- Abilita Bio Inc
- Actinobac Biomed Inc
- Aerie Pharmaceuticals Inc
- Aldeyra Therapeutics Inc
- Allegro Ophthalmics LLC
- Allgenesis Biotherapeutics Inc
- Allosterix Ltd
- Allysta Pharmaceuticals Inc
- APIRx Pharmaceuticals USA LLC
- Aramis Biosciences Inc
- Ascendia Pharmaceuticals Inc
- Aviara Pharmaceuticals Inc
- Avixgen Inc
- AxeroVision Inc
- Azura Ophthalmics Pty Ltd
- Bessor Pharma LLC
- BRIM Biotechnology Inc
- BSIM Therapeutics SA
- Cambium Medical Technologies LLC
- Cellix Bio Pvt Ltd
- Chengdu Kanghong Pharmaceuticals Group Co Ltd
- Chong Kun Dang Pharmaceutical Corp
- Cloudbreak Therapeutics LLC
- Curexsys GmbH
- Curigin Co Ltd
- Daewoo Pharmaceutical Co Ltd
- Daewoong Pharmaceutical Co Ltd
- DHP Korea Co Ltd
- Dompe Farmaceutici SpA
- EncuraGen Co Ltd
- Eye Bio Korea Co Ltd
- FirstString Research Inc
- GL Pharm Tech Corp
- Glaukos Corp
- Glia LLC
- H4Orphan Pharma
- HanAll Biopharma Co Ltd
- Huons Co Ltd
- Huons Global Co Ltd
- IACTA Pharmaceuticals Inc
- Icure Pharmaceutical Inc
- Ildong Pharmaceutical Co Ltd
- Intratus Inc
- Invitrx Therapeutics Inc
- Ipsen SA
- IVIEW Therapeutics Inc
- Japan Tobacco Inc
- Juvenescence UK Ltd
- Kala Pharmaceuticals Inc
- Kiora Pharmaceuticals Inc
- Kowa Co Ltd
- Kukje Pharmaceutical Industry Co Ltd
- Laboratoires Thea SA
- Link Biologics Ltd
- LTT Bio-Pharma Co Ltd
- Marinomed Biotech AG
- MC2 Therapeutics AS
- Medicon Pharmaceuticals Inc
- MediPrint Ophthalmics Inc
- MeiraGTx Holdings Plc
- Merck & Co Inc
- Mimetogen Pharmaceuticals Inc
- Mitotech SA
- MyX Therapeutics Inc
- Nanomerics Ltd
- Neuroptika Inc
- NicOx SA
- Ningbo Xijian Pharmaceutical Technology Co Ltd
- NovaCell Technology Inc
- Novaliq GmbH
- Novartis AG
- Noveome Biotherapeutics Inc
- OccuRx Pty Ltd
- Ocular Therapeutix Inc
- Oculis SA
- Ocumension Therapeutics
- OKYO Pharma Ltd
- OncoNOx ApS
- Ophrx Ltd
- Oyster Point Pharma Inc
- Palatin Technologies Inc
- Panag Pharma Inc
- PharmaResearch Co Ltd
- Pinotbio Inc
- Pleryon Therapeutics Ltd
- Proteris Biotech Inc
- Protokinetix Inc
- Qilu Pharmaceutical Co Ltd
- Quorum Innovations LLC
- Redwood Pharma AB
- RegeneRx Biopharmaceuticals Inc
- Reven Holdings Inc
- Rhizen Pharmaceuticals SA
- RHNanopharmacuticals LLC
- RiniSight Inc
- Rudacure Co Ltd
- Samjin Pharm Co Ltd
- Santen Pharmaceutical Co Ltd
- SCAI Therapeutics
- Seinda Pharmaceutical Guangzhou Corp
- Senju Pharmaceutical Co Ltd
- Serentrix LLC
- Shenzhen Evergreen Therapeutics Co Ltd
- SIFI SpA
- Silk Technologies Ltd
- Sinobioway Biomedical Co Ltd
- Skye Bioscience Inc
- Sol-Gel Technologies Ltd
- Stuart Therapeutics Inc
- Sun Pharmaceutical Industries Ltd
- Surface Pharmaceuticals Inc
- Surrozen Inc
- Sylentis SAU
- TaeJoon Pharmaceuticals Co Ltd
- TagCyx Biotechnologies
- Tarsius Pharma Ltd
- TearSolutions Inc
- Tetra Bio-Pharma Inc
- Vanda Pharmaceuticals Inc
- Viva Vision Biotech
- Yuyu Pharma Inc
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd
- Zhuhai Qiwei Biotechnology Co Ltd
- Keratoconjunctivitis Sicca (Dry Eye) – Drug Profiles
- (cyclosporine + trehalose) – Drug Profile
- A-197 – Drug Profile
- CT11 – Drug Profile
- ADX-103 – Drug Profile
- AG-80308 – Drug Profile
- AGN-231868 – Drug Profile
- AGN-242428 – Drug Profile
- AL-41A1 – Drug Profile
- ALG-1007 – Drug Profile
- ALY-688 – Drug Profile
- amlisimod – Drug Profile
- Antibodies to Antagonize CCR7 for Dry Eye and Lymphomas – Drug Profile
- Antibody for Dry Eye Disease – Drug Profile
- APIRx-1702 – Drug Profile
- Aptamer for Keratoconjunctivitis Sicca (Dry Eye) – Drug Profile
- AR-15512 – Drug Profile
- AVA-3486 – Drug Profile
- AVI-4015 – Drug Profile
- AXR-159 – Drug Profile
- AXR-270 – Drug Profile
- AZRAD-004 – Drug Profile
- AZRAD-005 – Drug Profile
- AZRAE-006 – Drug Profile
- betamethasone – Drug Profile
- Bi-specific Monoclonal Antibody for Keratoconjunctivitis Sicca (Dry Eye) and Sicca Syndrome (Sjogren) – Drug Profile
- Biologic for Keratoconjunctivitis Sicca (Dry Eye) – Drug Profile
- BRM-421 – Drug Profile
- CBT-006 – Drug Profile
- CBT-008 – Drug Profile
- cenegermin – Drug Profile
- CKD-352 – Drug Profile
- CLXOPH-621 – Drug Profile
- CS-001 – Drug Profile
- cyclosporine – Drug Profile
- cyclosporine SR – Drug Profile
- delgocitinib – Drug Profile
- dexamethasone SR – Drug Profile
- DHP-002 – Drug Profile
- diclofenac sodium – Drug Profile
- Drug for Dry Eye – Drug Profile
- Drug for Keratoconjunctivitis Sicca (Dry Eye) – Drug Profile
- EB-101 – Drug Profile
- EB-111 – Drug Profile
- ECN-1028 – Drug Profile
- ECN-3003 – Drug Profile
- EG-008 – Drug Profile
- EG-017 – Drug Profile
- Elate Ocular – Drug Profile
- fluticasone propionate – Drug Profile
- fonadelpar – Drug Profile
- HL-07 – Drug Profile
- HU-024 – Drug Profile
- IC-265 – Drug Profile
- ID-110410395 – Drug Profile
- ID-11901 – Drug Profile
- INT-11D001 – Drug Profile
- INT-11D002 – Drug Profile
- INT-11D003 – Drug Profile
- iVIEW-1601 – Drug Profile
- K-089 – Drug Profile
- K-161 – Drug Profile
- KH-732 – Drug Profile
- KIO-101 – Drug Profile
- KJ-14004 – Drug Profile
- KJ-16001 – Drug Profile
- L-002 – Drug Profile
- Lacripep – Drug Profile
- Leukothera – Drug Profile
- lifitegrast – Drug Profile
- Link_TSG6 – Drug Profile
- LLT-D2 – Drug Profile
- LLT-D3 – Drug Profile
- loteprednol etabonate – Drug Profile
- mycophenolic acid – Drug Profile
- NB-2222 – Drug Profile
- NCP-112 – Drug Profile
- nepidermin – Drug Profile
- nintedanib – Drug Profile
- NOV-03 – Drug Profile
- NOV-07 – Drug Profile
- NRO-1 – Drug Profile
- NTX-101 – Drug Profile
- OCS-02 – Drug Profile
- OCX-071 – Drug Profile
- OKYO-0101 – Drug Profile
- onternabez – Drug Profile
- Ophthalmology – Drug Profile
- OT-202 – Drug Profile
- OTX-DED – Drug Profile
- OX-1001 – Drug Profile
- OXT-328 – Drug Profile
- palovarotene – Drug Profile
- PH-007 – Drug Profile
- PH-013 – Drug Profile
- pilocarpine – Drug Profile
- PKX-001 – Drug Profile
- PL-265 – Drug Profile
- PL-9643 – Drug Profile
- plastoquinone decyl triphenylphosphonium bromide – Drug Profile
- PNA-003 – Drug Profile
- PPL-003 – Drug Profile
- progesterone – Drug Profile
- Protearin – Drug Profile
- QD-112 – Drug Profile
- Qi-401 – Drug Profile
- RCI-001 – Drug Profile
- rebamipide – Drug Profile
- recoflavone – Drug Profile
- reproxalap – Drug Profile
- RP-101 – Drug Profile
- RP-7214 – Drug Profile
- RPEC-1006A – Drug Profile
- RS-401 – Drug Profile
- SA-001 – Drug Profile
- salsalate – Drug Profile
- selenium sulfide – Drug Profile
- SER-114 – Drug Profile
- Sicca – Drug Profile
- simpinicline citrate – Drug Profile
- SJP-0132 – Drug Profile
- Small Molecule for Dry Eye and Meibomian Blepharitis – Drug Profile
- Small Molecule for Keratoconjunctivitis Sicca (Dry Eye) – Drug Profile
- Small Molecule to Agonize CB1 and CB2 for Keratoconjunctivitis Sicca – Drug Profile
- Small Molecules to Inhibit Transthyretin for Ophthalmology – Drug Profile
- SMR-001 – Drug Profile
- solithromycin – Drug Profile
- ST-100 – Drug Profile
- ST-266 – Drug Profile
- Stem Cell Therapy for Cardiovascular, Central Nervous System, Mouth and Dental Disorders, Ophthalmology and Respiratory Disorders – Drug Profile
- STN-1013500 – Drug Profile
- SY-201 – Drug Profile
- T-2769 – Drug Profile
- tacrolimus – Drug Profile
- tadekinig alfa – Drug Profile
- tanfanercept – Drug Profile
- tapinarof – Drug Profile
- tavilermide – Drug Profile
- timbetasin acetate – Drug Profile
- tivanisiran – Drug Profile
- TJO-083 – Drug Profile
- TJO-087 – Drug Profile
- TRS-01 – Drug Profile
- varenicline tartrate – Drug Profile
- VSJ-110 – Drug Profile
- VVN-001 – Drug Profile
- YY-101 – Drug Profile
- Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects
- Keratoconjunctivitis Sicca (Dry Eye) – Discontinued Products
- Keratoconjunctivitis Sicca (Dry Eye) – Product Development Milestones
- Featured News & Press Releases
- Jun 22, 2022: RegeneRx licensee to expand phase 3 clinical trial program with RGN-259
- Jun 18, 2022: Oyster Point Pharma Research selected for top 5 poster session at American Optometric Association's Optometry's Meeting
- Jun 08, 2022: Aldeyra Therapeutics achieves primary endpoint in phase 3 TRANQUILITY-2 trial in dry eye disease and intends to submit new drug application for symptoms and three sign endpoints of dry eye disease
- Jun 08, 2022: Aldeyra Therapeutics schedules conference call and webcast to announce top-line results from the phase 3 TRANQUILITY-2 trial in dry eye disease
- Jun 08, 2022: Zhaoke Ophthalmology: Voluntary announcement – New Drug Application of Cyclosporine A Ophthalmic Gel is accepted for review by the Center For Drug Evaluation
- May 25, 2022: Aerie doses first participant in Phase III dry eye disease therapy trial
- May 24, 2022: Aldeyra Therapeutics designates Schirmer test as sole primary endpoint in phase 3 TRANQUILITY-2 trial of reproxalap in dry eye disease
- May 03, 2022: Kala Pharmaceuticals announces new commercial and medicare coverage for EYSUVIS
- May 03, 2022: Bausch + Lomb presents data from second pivotal phase 3 trial of investigational treatment NOV03 (Perfluorohexyloctane) at the Association for Research in Vision and Ophthalmology Annual Meeting
- May 02, 2022: Nicox at ARVO 2022: Presentation of clinical Phase 2 results on NCX 4251
- May 02, 2022: Palatin to present on PL9643 at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference
- Apr 27, 2022: Oyster Point Pharma to present new analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022
- Apr 26, 2022: Novaliq presents data from second phase 3 trial of investigational treatment Cyclasol (0.1% cyclosporine ophthalmic solution) at the American Society of Cataract and Refractive Surgery annual meeting
- Apr 26, 2022: Bausch + Lomb will present new scientific data during the American Society of Cataract and Refractive Surgery Annual Meeting
- Apr 25, 2022: Bausch + Lomb presents data from first pivotal phase 3 trial of investigational treatment NOV03 (Perfluorohexyloctane) at the American Society of Cataract and Refractive Surgery Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Universities/Institutes, 2022
- Table 9: Products under Development by Companies, 2022
- Table 10: Products under Development by Companies, 2022 (Contd..1)
- Table 11: Products under Development by Companies, 2022 (Contd..2)
- Table 12: Products under Development by Companies, 2022 (Contd..3)
- Table 13: Products under Development by Companies, 2022 (Contd..4)
- Table 14: Products under Development by Companies, 2022 (Contd..5)
- Table 15: Products under Development by Companies, 2022 (Contd..6)
- Table 16: Products under Development by Companies, 2022 (Contd..7)
- Table 17: Products under Development by Companies, 2022 (Contd..8)
- Table 18: Products under Development by Universities/Institutes, 2022
- Table 19: Number of Products by Stage and Target, 2022
- Table 20: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 21: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 22: Number of Products by Stage and Mechanism of Action, 2022
- Table 23: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 24: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 25: Number of Products by Stage and Route of Administration, 2022
- Table 26: Number of Products by Stage and Molecule Type, 2022
- Table 27: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by AB2 Bio Ltd, 2022
- Table 28: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by AbbVie Inc, 2022
- Table 29: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Abilita Bio Inc, 2022
- Table 30: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Actinobac Biomed Inc, 2022
- Table 31: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Aerie Pharmaceuticals Inc, 2022
- Table 32: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Aldeyra Therapeutics Inc, 2022
- Table 33: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Allegro Ophthalmics LLC, 2022
- Table 34: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Allgenesis Biotherapeutics Inc, 2022
- Table 35: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Allosterix Ltd, 2022
- Table 36: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Allysta Pharmaceuticals Inc, 2022
- Table 37: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by APIRx Pharmaceuticals USA LLC, 2022
- Table 38: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Aramis Biosciences Inc, 2022
- Table 39: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ascendia Pharmaceuticals Inc, 2022
- Table 40: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Aviara Pharmaceuticals Inc, 2022
- Table 41: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Avixgen Inc, 2022
- Table 42: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by AxeroVision Inc, 2022
- Table 43: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Azura Ophthalmics Pty Ltd, 2022
- Table 44: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Bessor Pharma LLC, 2022
- Table 45: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by BRIM Biotechnology Inc, 2022
- Table 46: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by BSIM Therapeutics SA, 2022
- Table 47: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Cambium Medical Technologies LLC, 2022
- Table 48: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Cellix Bio Pvt Ltd, 2022
- Table 49: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022
- Table 50: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Chong Kun Dang Pharmaceutical Corp, 2022
- Table 51: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Cloudbreak Therapeutics LLC, 2022
- Table 52: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Curexsys GmbH, 2022
- Table 53: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Curigin Co Ltd, 2022
- Table 54: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Daewoo Pharmaceutical Co Ltd, 2022
- Table 55: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Table 56: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by DHP Korea Co Ltd, 2022
- Table 57: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Dompe Farmaceutici SpA, 2022
- Table 58: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by EncuraGen Co Ltd, 2022
- Table 59: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Eye Bio Korea Co Ltd, 2022
- Table 60: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by FirstString Research Inc, 2022
- Table 61: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by GL Pharm Tech Corp, 2022
- Table 62: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Glaukos Corp, 2022
- Table 63: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Glia LLC, 2022
- Table 64: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by H4Orphan Pharma, 2022
- Table 65: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by HanAll Biopharma Co Ltd, 2022
- Table 66: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Huons Co Ltd, 2022
- Table 67: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Huons Global Co Ltd, 2022
- Table 68: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by IACTA Pharmaceuticals Inc, 2022
- Table 69: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Icure Pharmaceutical Inc, 2022
- Table 70: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ildong Pharmaceutical Co Ltd, 2022
- Table 71: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Intratus Inc, 2022
- Table 72: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Invitrx Therapeutics Inc, 2022
- Table 73: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ipsen SA, 2022
- Table 74: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by IVIEW Therapeutics Inc, 2022
- Table 75: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Japan Tobacco Inc, 2022
- Table 76: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Juvenescence UK Ltd, 2022
- Table 77: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Kala Pharmaceuticals Inc, 2022
- Table 78: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Kiora Pharmaceuticals Inc, 2022
- Table 79: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Kowa Co Ltd, 2022
- Table 80: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2022
- Table 81: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Laboratoires Thea SA, 2022
- Table 82: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Link Biologics Ltd, 2022
- Table 83: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by LTT Bio-Pharma Co Ltd, 2022
- Table 84: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Marinomed Biotech AG, 2022
- Table 85: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by MC2 Therapeutics AS, 2022
- Table 86: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Medicon Pharmaceuticals Inc, 2022
- Table 87: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by MediPrint Ophthalmics Inc, 2022
- Table 88: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by MeiraGTx Holdings Plc, 2022
- Table 89: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Merck & Co Inc, 2022
- Table 90: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Mimetogen Pharmaceuticals Inc, 2022
- Table 91: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Mitotech SA, 2022
- Table 92: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by MyX Therapeutics Inc, 2022
- Table 93: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Nanomerics Ltd, 2022
- Table 94: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Neuroptika Inc, 2022
- Table 95: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by NicOx SA, 2022
- Table 96: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ningbo Xijian Pharmaceutical Technology Co Ltd, 2022
- Table 97: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by NovaCell Technology Inc, 2022
- Table 98: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Novaliq GmbH, 2022
- Table 99: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Novartis AG, 2022
- Table 100: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Noveome Biotherapeutics Inc, 2022
- Table 101: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by OccuRx Pty Ltd, 2022
- Table 102: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ocular Therapeutix Inc, 2022
- Table 103: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Oculis SA, 2022
- Table 104: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ocumension Therapeutics, 2022
- Table 105: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by OKYO Pharma Ltd, 2022
- Table 106: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by OncoNOx ApS, 2022
- Table 107: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Ophrx Ltd, 2022
- Table 108: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Oyster Point Pharma Inc, 2022
- Table 109: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Palatin Technologies Inc, 2022
- Table 110: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Panag Pharma Inc, 2022
- Table 111: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by PharmaResearch Co Ltd, 2022
- Table 112: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Pinotbio Inc, 2022
- Table 113: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Pleryon Therapeutics Ltd, 2022
- Table 114: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Proteris Biotech Inc, 2022
- Table 115: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Protokinetix Inc, 2022
- Table 116: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
- Table 117: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Quorum Innovations LLC, 2022
- Table 118: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Redwood Pharma AB, 2022
- Table 119: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by RegeneRx Biopharmaceuticals Inc, 2022
- Table 120: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Reven Holdings Inc, 2022
- Table 121: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Rhizen Pharmaceuticals SA, 2022
- Table 122: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by RHNanopharmacuticals LLC, 2022
- Table 123: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by RiniSight Inc, 2022
- Table 124: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Rudacure Co Ltd, 2022
- Table 125: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Samjin Pharm Co Ltd, 2022
- Table 126: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Santen Pharmaceutical Co Ltd, 2022
- Table 127: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by SCAI Therapeutics, 2022
- Table 128: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Seinda Pharmaceutical Guangzhou Corp, 2022
- Table 129: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Senju Pharmaceutical Co Ltd, 2022
- Table 130: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Serentrix LLC, 2022
- Table 131: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Shenzhen Evergreen Therapeutics Co Ltd, 2022
- Table 132: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by SIFI SpA, 2022
- Table 133: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Silk Technologies Ltd, 2022
- Table 134: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Sinobioway Biomedical Co Ltd, 2022
- Table 135: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Skye Bioscience Inc, 2022
- Table 136: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Sol-Gel Technologies Ltd, 2022
- Table 137: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Stuart Therapeutics Inc, 2022
- Table 138: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Sun Pharmaceutical Industries Ltd, 2022
- Table 139: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Surface Pharmaceuticals Inc, 2022
- Table 140: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Surrozen Inc, 2022
- Table 141: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Sylentis SAU, 2022
- Table 142: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by TaeJoon Pharmaceuticals Co Ltd, 2022
- Table 143: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by TagCyx Biotechnologies, 2022
- Table 144: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Tarsius Pharma Ltd, 2022
- Table 145: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by TearSolutions Inc, 2022
- Table 146: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Tetra Bio-Pharma Inc, 2022
- Table 147: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Vanda Pharmaceuticals Inc, 2022
- Table 148: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Viva Vision Biotech, 2022
- Table 149: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Yuyu Pharma Inc, 2022
- Table 150: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd, 2022
- Table 151: Keratoconjunctivitis Sicca (Dry Eye) – Pipeline by Zhuhai Qiwei Biotechnology Co Ltd, 2022
- Table 152: Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects, 2022
- Table 153: Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects, 2022 (Contd..1)
- Table 154: Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects, 2022 (Contd..2)
- Table 155: Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects, 2022 (Contd..3)
- Table 156: Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects, 2022 (Contd..4)
- Table 157: Keratoconjunctivitis Sicca (Dry Eye) – Dormant Projects, 2022 (Contd..5)
- Table 158: Keratoconjunctivitis Sicca (Dry Eye) – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Keratoconjunctivitis Sicca (Dry Eye), 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.